Compare Bristol-Myers Squibb Co (BMY) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Vertiv Holdings Co — how do they compare? Bristol-Myers Squibb Co trades at $58.7 (market cap $116.30B), while Vertiv Holdings Co trades at $304.46 (market cap $116.61B). The key difference: Bristol-Myers Squibb Co and Vertiv Holdings Co are close in size by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | VRT | |
|---|---|---|
Market Cap | $116.30B | $116.61B |
Sector | Health | Technology |
52-Week High | $62.37 | $376.23 |
52-Week Low | $42.60 | $121.82 |
Enterprise Value | $152.24B | $117.37B |
Dividend Yield | 4.42% | 0.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Vertiv Holdings (VRT) trades at $305.87, down 4.07% today, amid strong fundamental performance with consistent earnings beats and robust AI-driven demand. The stock shows neutral technical signals with support at $300 and resistance at $314, while maintaining impressive profitability metrics including 45.1% ROE and 14.37% net margin. Recent news highlights Vertiv's $15 billion order backlog and expansion in Malaysia to capitalize on AI infrastructure growth.
The outlook remains positive with 94.7% analyst buy ratings and a $407.45 consensus target, representing 33% upside potential. Key risks include premium valuation multiples (P/E 76.28) and competitive pressures, but strong cash flow generation and AI infrastructure tailwinds support continued growth momentum through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
